Novo Nordisk partnering with Hims, LifeMD to sell Wegovy, Bloomberg reports

Novo Nordisk (NVO) is partnering with Hims & Hers (HIMS), LifeMD (LFMD), Ro, and other telehealth companies to offer Wegovy, its popular weight loss drug, to more U.S. patients, Bloomberg’s Madison Muller reports. The telehealth companies will sell a month’s supply of Wegovy through NovoCare, Novo Nordisk’s direct-to-consumer pharmacy platform, starting at $499, a discount of nearly 63% from the drug’s U.S. list price, before subscription fees, according to the report. Rival Eli Lilly (LLY) previously teamed up with Ro and other telehealth firms to distribute lower cost vials of Zepbound, its obesity medication.